Sign in
CYTH Stock Price, Chart, Stats & News
Cyclo Therapeutics, Inc.
Save
23.59M
Market cap
–
Current P/E
–
Forward P/E
CYTH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.85% |
Operating margin | -1862.69% |
Pretax margin | -1863.36% |
Net margin | -1863.36% |
Effective tax rate | – |
ROA | -151.40% |
ROE | -730.48% |
D/E | 0.22x |
Interest coverage ratio | – |
CYTH valuation
P/E | – |
P/S | 21.92x |
P/B | 2.47x |
P/CF | -0.73x |
P/FCF | -1.46x |
P/OCF | -0.73x |
PEG | 0.26x |
EV multiple | -1.59x |
About
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease.
Similar securities
Based on sector and market capitalization
Report issue